No Data
No Data
Wanbang Pharmaceutical (301520.SZ): No synthetic biotechnology available at the moment.
On July 31st, Gelonhui reported that Wanbang Pharmaceutical (301520.SZ) stated on an investor interaction platform that the company currently does not have any biotechnology synthesis.
One World Pharma (301520.SZ): There are projects related to anti-cancer and anti-HIV in the clinical research business.
A shareholder asked Wanbang Pharmaceutical (301520.SZ) on the investor interaction platform on July 24th, "Does your company have any cancer or AIDS projects? What are the current ongoing projects?" The company stated in response that their clinical research business includes projects related to cancer and AIDS, and all are currently underway.
Wanbang Pharmaceutical (301520.SZ): The company has not yet used AI technology in its research and development process.
On July 24th, Gelunhui reported that Wanbang Medicine (301520.SZ) stated on the investor interaction platform that AI technology has not been used in the company's research and development process.
Wanbang Medicine (301520.SZ) will distribute 5 yuan for every 10 shares in 2023. The equity registration day is June 20th.
Wanbang Pharmaceutical (301520.SZ) announced that the company will implement the annual equity distribution for 2023, with 10 shares per...
Wanbang Pharmaceutical (301520.SZ): has developed a sample analysis method for Semaglutide.
On June 5th, Gelon Hui reported that Wanbang Pharma (301520.SZ) has developed a sample analysis method for Simcereglutide, which is one of the clinical research links. At present, there are no related orders.
Wanbang Pharmaceutical (301520.SZ): The company has not yet carried out drug research and development work for the KP.2 variant
Gelonghui, May 20 | Wanbang Pharmaceutical (301520.SZ) said on the investor interactive platform that the company has not yet carried out drug research and development work on the KP.2 variant.
No Data